Progress of chimeric antigen receptor T cells in the treatment of hematologic malignancies：reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.02.001
- VernacularTitle:嵌合抗原受体T细胞的应用进展与挑战：第57届美国血液学会年会报道
- Author:
Xuhua ZHANG
;
Yongping SONG
- Publication Type:Journal Article
- Keywords:
Chimeric antigen receptor T cell;
Immunotherapy;
Hematologic malignancy;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(2):65-68
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T cells (CAR-T), one of the most promising cancer immunotherapy, has attracted much attention in the 57th American Society of Hematology (ASH) annual meeting. CAR-T therapy has obtained significant effect on leukemia and lymphoma and the latest research results are also inspiring in the 57th ASH annual meeting. It is an important task that how to combine CAR-T therapy with the traditional methods of treatment and the immune checkpoint blocking antibodies and small-molecule-targeted drugs to achieve the best effect. This paper will review the progress of CAR-T in the treatment of hematologic malignancies.
